Skip to main content
. 2019 May 2;12:179–191. doi: 10.2147/CEG.S150908

Table 3.

Tofacitinib as induction therapy in Crohn’s disease

Phase/study Treatment Size Clinical response Clinical remission
Phase II Sandborn et al 2014 Placebo
1 mg BID
5 mg BID
15 mg BID
34
36
34
35
47%
36% (p=0.467)
58% (p=0.466)
46% (p≥0.999)
21%
31% (p=0.417)
24% (p=0.776)
14% (p=0.540)
Phase IIb Induction Panés et al 2017 Placebo
5 mg BID
10 mg BID
91
86
86
62%
76.5% (p<0.05)
74.4% (p>0.05)
36.7%
43% (0.325)
43% (0.392)

Abbreviation: BID, twice daily.

HHS Vulnerability Disclosure